Applied Nutrition said revenue for the year to 31 July rose 50% to £160m and adjusted EBITDA 40% to about £43.3m, both ahead of consensus, with full results due on 16 November.
Revenue compares with £107m a year earlier, and adjusted EBITDA (earnings before interest, tax, depreciation and amortisation, stripped of one-off items and share-based payments) with £30.9m, the sports nutrition group said.
The consensus the company calculated immediately beforehand was £148.4m for revenue and £42.0m for adjusted EBITDA. Revenue therefore came in £11.6m above that figure, and EBITDA £1.3m above it.
The EBITDA figure excludes any amounts from the trade and assets of Nutrablend, which Applied Nutrition acquired in June. All FY26 figures remain subject to audit, and the full accounts are scheduled for publication on 16 November.
Net cash, excluding IFRS 16 liabilities (lease obligations), was £15.9m at the year end. That followed the Nutrablend purchase, spending on the production extension and higher working capital. Net cash was £18.5m at the end of the previous year.
For the year to 31 July 2027, the board expects adjusted EBITDA of about £49m, up 13%, and revenue of about £205m. Consensus for those measures stood at £47.7m and £186.2m. The revenue guide is about 28% above the FY26 figure.
The company said the EBITDA margin is expected to fall slightly from FY26 levels. It put that down to a bigger revenue contribution from the US, a greater share of whey-based sales, partly after the relaunch of Critical Whey, and “significantly higher whey protein costs”.
On the figures given, the margin would move from about 27% in FY26 to about 24% in FY27, based on £43.3m of EBITDA on £160m of revenue and £49m on £205m.
The growth follows a year in which FY25 results, published on 10 November 2025, showed revenue up 24.2% to £107.1m and adjusted EBITDA up 18.8% to £30.9m. Unadjusted operating profit then rose 18.6% to £28.1m.
Those results also said the company’s production capacity could support revenue of about £200m, with £2.0m to £2.5m of investment over 18 to 24 months planned to lift it to about £300m.
The FY27 revenue guide of about £205m sits above the lower of those two capacity figures.
On 1 June 2026 the company had said trading was ahead of expectations and announced the acquisition of a US manufacturing facility. It sells in more than 85 countries and largely operates a business-to-business model, with products developed in Knowsley, Liverpool, and Buffalo, New York.
The annual general meeting is set for 14 January 2027, with interim results due in March 2027.






